Meeting
2018 Genitourinary Cancers Symposium
Erdafitinib (ERDA; JNJ-42756493), a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRa): Phase 2 continuous versus intermittent dosing.
Authors
Yohann Loriot
Institut Gustave Roussy, Villejuif, France
Yohann Loriot , Andrea Necchi , Se Hoon Park , Jesús García-Donas , Robert A Huddart , Earle Frederick Burgess , Mark T. Fleming , Arash Rezazadeh , Begona Mellado , Sergei Varlamov , Monika Joshi , Ignacio Duran , Anne OHagan , Anjali Narayan Avadhani , Bob Zhong , Kim Stuyckens , Anne-Gaëlle Dosne , Arlene O. Siefker-Radtke
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer, Urothelial Carcinoma, and Penile, Urethral, and Testicular Cancers
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Urothelial Carcinoma
Clinical Trial Registration Number
NCT02365597
Citation
J Clin Oncol 36, 2018 (suppl 6S; abstr 411)
DOI
10.1200/JCO.2018.36.6_suppl.411
Abstract #
411
Poster Bd #
A8
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase 2 multi-arm study of magrolimab in combination with docetaxel in patients with locally advanced or metastatic solid tumors: ELEVATE Lung and UC.
First Author: Vivek Subbiah
Poster
2020 Genitourinary Cancers Symposium
![Does escalation results from phase Ib/II Norse study of erdafitinib (ERDA) + PD-1 inhibitor JNJ-63723283 (Cetrelimab [CET]) in patients (pts) with metastatic or locally advanced urothelial carcinoma (mUC) and selected fibroblast growth factor receptor (FGFR) gene alterations.](https://d201v5jt9ylckg.cloudfront.net/257/14745/183995/183995_poster_pv.jpg)
Does escalation results from phase Ib/II Norse study of erdafitinib (ERDA) + PD-1 inhibitor JNJ-63723283 (Cetrelimab [CET]) in patients (pts) with metastatic or locally advanced urothelial carcinoma (mUC) and selected fibroblast growth factor receptor (FGFR) gene alterations.
First Author: Victor Moreno
Poster
2023 ASCO Annual Meeting
A phase 2 randomized study of magrolimab combination therapy in adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): ELEVATE-TNBC.
First Author: Natalie Rainey
Poster
2021 Genitourinary Cancers Symposium
Management of fibroblast growth factor receptor inhibitor (FGFRi) treatment-emergent adverse events (TEAEs) of interest in patients (Pts) with locally advanced or metastatic urothelial carcinoma (mUC).
First Author: Arlene O. Siefker-Radtke